{"id":6317,"date":"2022-02-21T14:00:00","date_gmt":"2022-02-21T14:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3668187_CN68187_0"},"modified":"2022-02-21T14:00:00","modified_gmt":"2022-02-21T14:00:00","slug":"daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=6317","title":{"rendered":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1676530\/Daewoong_Pharmaceuticals_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b>Recorded operating profit <span class=\"xn-money\">KRW 88.9 billion<\/span> and net profit <span class=\"xn-money\">KRW 31.6 billion<\/span> in 2021 with the outcome of its relentless focus on R&amp;D<\/b> <\/li>\n<li><b>Attributed to export upswing of Nabota, <span class=\"xn-money\">KRW 1.1 trillion<\/span> overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs<\/b><\/li>\n<\/ul>\n<p><span class=\"xn-location\">SEOUL, South Korea<\/span>, <span class=\"xn-chron\">Feb. 21, 2022<\/span> \/PRNewswire\/ &#8212;&nbsp;Daewoong Pharmaceutical (Daewoong) (CEO <span class=\"xn-person\">Sengho Jeon<\/span> &amp; <span class=\"xn-person\">Changjae Lee<\/span>) recently announced its 2021 financial results with its all-time high revenue. The consolidated annual sales in 2021 was KRW&nbsp;1.153&nbsp;trillion rose by 9.2% y-o-y, and operating profit and net profit marked KRW&nbsp;88.9&nbsp;billion and KRW&nbsp;31.6&nbsp;billion, up 423% and 31.3% y-o-y respectively. According to separate financial statement, Daewoong delivered KRW&nbsp;1.055&nbsp;trillion in sales, KRW&nbsp;95.5&nbsp;billion in operating profit and KRW&nbsp;40.5&nbsp;billion in net profit.<\/p>\n<p>The increase in last year&#8217;s sales and record operating sales reflected KRW&nbsp;1.1 trillion worth overseas technology transfer of Fexuclue tablets (ingredient name: fexuprazan hydrochloride), Daewoong&#8217;s gastroesophageal reflux disease drugs which received new drug approval by the Ministry of Food and Drug Safety of Korea late last year, rapid export growth&nbsp;of Nabota, a botulinum toxin product which had settled all legal disputes in and outside Korea and is currently marketed under the name Jeuveau in the U.S., and a stable growth of highly profitable ethical-the-counter (ETC) drugs.<\/p>\n<p>Sales of ETC drugs increased to KRW&nbsp;778&nbsp;billion from KRW&nbsp;709.4&nbsp;billion a year ago, driven by a strong sales growth of highly profitable products, such as an oncology drug Luphere Depot injection and a hyperlipidemia drug Crezet tablets. Daewoong is to further accelerate its growth in ETC drugs, with the upcoming release of Fexuclue 40 mg film-coated tablets in the first half of this year.<\/p>\n<p>Sales of over-the-counter (OTC) drugs marked KRW&nbsp;114.4 billion, slightly up from KRW&nbsp;113.3&nbsp;billion in the previous year. In response to the growth of health supplements market, Daewoong has been actively expanding its businesses by promoting a liver-specialized brand Ener Thistle and launching Say Health for the hospital channels.<\/p>\n<p>Sales of Nabota surged to KRW&nbsp;79.6&nbsp;billion from KRW&nbsp;50.4&nbsp;billion a year ago. Its domestic sales nearly doubled y-o-y, and overseas sales increased by more than 60 percent, centered on the U.S. in which the company&#8217;s all botulinum toxin-related lawsuits and&nbsp;business uncertainties&nbsp;were resolved favorably to Daewoong.&nbsp;Nabota is also expected to launch in <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">China<\/span> within this year, following its record-high quarterly sales figures in the U.S. since Q2 2021.<\/p>\n<p>Global sales except Nabota sharply rose to KRW&nbsp;36.9&nbsp;billion from KRW&nbsp;14.8&nbsp;billion in the previous year. Daewoong signed a series of technology export contracts on&nbsp;Fexuclue tablets, which received new drug approval at the end of last year. The contracts totaling KRW&nbsp;1.1&nbsp;trillion thereby allowed the company to secure the sales channels penetrating the global antiulcer drug market estimated about KRW&nbsp;40&nbsp;trillion, including the two largest markets, the U.S. and <span class=\"xn-location\">China<\/span>, and Central and <span class=\"xn-location\">South America<\/span> and the <span class=\"xn-location\">Middle East<\/span>.<\/p>\n<p>In 2021, Daewoong invested KRW&nbsp;127.3&nbsp;billion, which exceeds 10% of its annual sales revenue, in R&amp;D, and created the business cycle that the R&amp;D outcome leads the growth of sales and operating profit and assures new growth engine. The company saw business upturns and made key achievements last year; it received new drug approval of Fexuclue tablets and generated more than <span class=\"xn-money\">KRW 1 trillion<\/span> profits from overseas technology transfer, and this year is expected to introduce Nabota to the world&#8217;s second and third largest botulinum toxin markets, <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">China<\/span>. In <span class=\"xn-location\">China<\/span>, Daewoong has already submitted a biologics license application. Furthermore, the phase-3 trial of Enavogliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for diabetes first developed by a Korean pharmaceutical company, was successfully completed earlier this year and showed a strong possibility that Daewoong will successively introduce new drug, following Fexuclue tablets.<\/p>\n<p>&#8220;In 2021, we were pleased that our robust R&amp;D investment and efforts drove major results throughout the year, improving social&nbsp;wellbeing&nbsp;with new drug and reporting all-time high revenue,&#8221; said <span class=\"xn-person\">Sengho Jeon<\/span>, Daewoong Pharmaceutical&nbsp;CEO. &#8220;We will propel new drug development and business growth simultaneously this year, in addition to introducing our excellent drugs, including Fexuclue tablets and Nabota, to Korean and overseas markets and accelerating new drug development through proactive partnership.&#8221;<\/p>\n<p>Daewoong also considers that the prolonged risks and disputes associated with its botulinum toxin business were completely and favorably resolved in 2021, as the criminal lawsuit filed by its competitor was cleared in Korea, and the final ruling of the U.S. International Trade Commission was invalidated, including the import ban. Daewoong sees 2022 will be another record year that it starts to bring tangible improvement in profitability.<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN68187&amp;sd=2022-02-21\"> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development-301486327.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development-301486327.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&amp;D Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, South Korea, Feb. 21, 2022 \/PRNewswire\/ &#8212;&nbsp;Daewoong Pharmaceutical (Daewoong) [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":6318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-6317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=6317\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog\" \/>\n<meta property=\"og:description\" content=\"Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&amp;D Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, South Korea, Feb. 21, 2022 \/PRNewswire\/ &#8212;&nbsp;Daewoong Pharmaceutical (Daewoong) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=6317\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-21T14:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"597\" \/>\n\t<meta property=\"og:image:height\" content=\"129\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development\",\"datePublished\":\"2022-02-21T14:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317\"},\"wordCount\":825,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317\",\"name\":\"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg\",\"datePublished\":\"2022-02-21T14:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg\",\"width\":597,\"height\":129},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6317#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=6317","og_locale":"en_US","og_type":"article","og_title":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog","og_description":"Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&amp;D Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, South Korea, Feb. 21, 2022 \/PRNewswire\/ &#8212;&nbsp;Daewoong Pharmaceutical (Daewoong) [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=6317","og_site_name":"My Blog","article_published_time":"2022-02-21T14:00:00+00:00","og_image":[{"width":597,"height":129,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg","type":"image\/jpeg"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=6317#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development","datePublished":"2022-02-21T14:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317"},"wordCount":825,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=6317","url":"https:\/\/transmediavictoria.net.au\/?p=6317","name":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg","datePublished":"2022-02-21T14:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6317#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=6317"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=6317#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/02\/daewoong-pharmaceutical-posts-record-annual-revenue-in-2021-with-export-growth-of-nabota-and-new-drug-development.jpg","width":597,"height":129},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=6317#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/6317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6317"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/6317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/6318"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}